Anzeige
Mehr »
Login
Sonntag, 07.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Bam Bam Resources und die Mega-Kupferlagerstätte in Teslas Hinterhof!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 903662 ISIN: SE0000273294 Ticker-Symbol: MVR 
Frankfurt
05.03.21
10:37 Uhr
0,816 Euro
-0,019
-2,28 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIVIR AB Chart 1 Jahr
5-Tage-Chart
MEDIVIR AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,8190,85718:51

Aktuelle News zur MEDIVIR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MEDIVIR Aktie jetzt für 0€ handeln
26.02.Medivir AB reports Q4 results-
26.02.MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 20204
11.02.Nasdaq Stockholm AB: Delisting of paid subscription shares in Medivir AB (15/21)223The paid subscription shares in Medivir AB will be delisted. Last trading day for MVIR BTA B will be on February 15, 2021. Instrument: Paid subscription shares --------------------------------------- Short...
► Artikel lesen
10.02.Medivir strikes licensing deal with Ubiquigent3
10.02.Medivir enters into licensing agreement with Ubiquigent for preclinical program USP7-
10.02.Ubiquigent Limited: Medivir Licenses Preclinical USP7 Program to Ubiquigent147Ubiquigent Limited (Ubiquigent) announced today that it has entered into a license agreement with Medivir AB (Nasdaq Stockholm: MVIR) for Medivir's preclinical USP7 research program. Under the terms...
► Artikel lesen
08.02.Notice of extraordinary general meeting of Medivir AB (publ)1
07.02.MEDIVIR PROPOSES DIRECTED ISSUE OF APPROXIMATELY SEK 28 MILLION TO THE COMPANY'S EXISTING SPECIALIST INVESTOR AB LINC7
19.01.Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Medivir AB (6/21)232With effect from January 20, 2021, the subscription rights in Medivir AB will be traded on the list for Equity rights. Trading will continue up until and including February 01, 2021. Instrument: ...
► Artikel lesen
14.01.XFRA CAPITAL ADJUSTMENT INFORMATION - 14.01.2021290CAPITAL ADJUSTMENT INFORMATION - 14.01.2021:Das Instrument SCT GB0007908733 SSE PLC LS-,50 EQUITY wird ex Kapitalmassnahme gehandelt am 14.01.2021 The instrument SCT GB0007908733 SSE PLC LS-,50 EQUITY...
► Artikel lesen
13.01.Resolutions at the extraordinary general meeting in Medivir on 13 January 20212
12.01.Medivir sells global rights of birinapant to IGM Biosciences3
12.01.Medivir presents MIV-818 data at ASCO Gastrointestinal Cancers Symposium2
12.01.IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant2
12.01.Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant1
11.12.20Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant5
11.12.20Notice of extraordinary general meeting of Medivir AB (publ)1
10.11.20Medivir AB reports Q3 results5
10.11.20MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 20201
05.10.20Medivir appoints Dr. Tom Morris as interim Chief Medical Officer1
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1